TargetMol

Forfenimex

Product Code:
 
TAR-T31847
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T31847-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31847-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31847-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Forfenimex is a newly discovered low molecular weight immunomodulator.
CAS:
71522-58-2
Formula:
C9H11NO4
Molecular Weight:
197.19
Purity:
0.98
SMILES:
N[C@H](C(O)=O)c1ccc(CO)c(O)c1

References

1. Murphy KT, Wardak A, Beckett MA, Lopez CA, Mehta N, Kimchi E, Salloum RM, Jaskowiak NT, Posner MC, Ohno T, Kufe DW, Weichselbaum RR, Mauceri HJ. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep;56(3):317-21. Epub 2005 May 11. PubMed PMID: 15887016. 2. Tanaka M, Hori Y, Sakai F, Ueda H, Goto T, Okuhara M, Tsuda Y, Okada Y. WS1279, a novel lipopeptide isolated from Streptomyces willmorei. Biological activities. J Antibiot (Tokyo). 1993 Nov;46(11):1699-706. PubMed PMID: 8270492. 3. Koyama Y, Huang SP, Ikeda D, Hamada M, Kondo S, Takeuchi T. Orally absorbable D-forphenicinol-cephalosporins. J Antibiot (Tokyo). 1989 Jun;42(6):993-9. PubMed PMID: 2737957. 4. Ishihara K, Hayasaka K, Yamazaki N. Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. J Invest Dermatol. 1989 May;92(5 Suppl):326S-328s. PubMed PMID: 2469742.